ArticleOncogene2021

RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia.

David Koschut et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.